• Explore /
  • Poster
  • / Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.

Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.

Abstract Poster

Authors

null

Ulrich Herrlinger

Division of Clinical Neurooncology, Department of Neurology and Center of Integrated Oncology Cologne/Bonn, University of Bonn, Bonn, Germany

Ulrich Herrlinger , Niklas Schaefer , Joachim Peter Steinbach , Astrid Weyerbrock , Peter Hau , Roland Goldbrunner , Franziska Friedrich , Veit Rohde , Florian Ringel , Christian Braun , Ralf Kohnen , Barbara Leutgeb , Claus Belka , Horst Urbach , Walter Stummer , Martin Glas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

No.: 2009-010390-21

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 2042^)

DOI

10.1200/jco.2014.32.15_suppl.2042

Abstract #

2042^

Poster Bd #

7

Abstract Disclosures

Similar Posters

First Author: Martin Kelly Nicholas

First Author: A. M. P. Omuro

First Author: Peijing Li

Poster

2020 ASCO Virtual Scientific Program

Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.

Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.

First Author: Wenyin Shi